Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: Median survival was 14.8 months in the docetaxel group and 12.6 months in the control group. Median times to disease progression were 9.0 months ( docetaxel arm) and 7.6 months (control arm). There were three complete responses and 25 partial responses in patients treated with docetaxel who were evaluable for response (n = 101). Docetaxel was well-tolerated: 103 patients (77%) received all three planned cycles. The major toxicity was grade 4 neutropenia (69 patients, 55%) and neutropenic fever (eight patients, 6%). Radiotherapy was well-tolerated after docetaxel administration. CONCLUSIONS: Neoadjuvant docetaxel is generally well-tolerated and shows a promising trend towards longer survival in patients with NSCLC.
|
Authors | K V Mattson, R P Abratt, G ten Velde, K Krofta |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 14
Issue 1
Pg. 116-22
(Jan 2003)
ISSN: 0923-7534 [Print] England |
PMID | 12488303
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Taxoids
- Docetaxel
- Paclitaxel
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, radiotherapy)
- Case-Control Studies
- Combined Modality Therapy
- Disease Progression
- Docetaxel
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms
(drug therapy, radiotherapy, surgery)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Paclitaxel
(adverse effects, analogs & derivatives, therapeutic use)
- Postoperative Period
- Safety
- Survival Rate
- Taxoids
- Treatment Outcome
|